Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.40 |
| ▸ | ICMT | O60725 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6967005 | 0.86 | DPP4 (0.41) | CYP11B2ICMTARNR3C1 | |
| SCHEMBL6966551 | 0.79 | METAP2 (0.43) | PPARDPPARAALDH1A1POLB | |
| SCHEMBL6961566 | 0.79 | SLC6A2 (0.43) | PPARDPPARAICMTLRRK2 | |
| SCHEMBL6966926 | 0.77 | ALDH1A1 (0.33) | CYP11B2ALDH1A1POLB | |
| SCHEMBL6941777 | 0.73 | AR (0.49) | PPARDPPARACYP11B2ICMTAR | |
| SCHEMBL6967672 | 0.73 | L3MBTL1 (0.43) | MAPT | |
| SCHEMBL6961211 | 0.70 | METAP2 (0.43) | ALDH1A1 | |
| SCHEMBL6944897 | 0.70 | TRPV4 (0.56) | ICMTARUSP2MAPTALDH1A1 | |
| SCHEMBL11749561 | 0.68 | AR (0.50) | PPARDPPARAICMTARUSP2 | |
| SCHEMBL523884 | 0.68 | USP2 (0.48) | PPARDPPARAICMTARUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | claimed |
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | PPARD 846/4885PPARA 1198/4885CYP11B2 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.